| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 3.0K | 9.6% | 5.3% |
| Total Income | 3.0K | 9.6% | 5.3% |
| Expenditure | 2.7K | 4.1% | 4.7% |
| PBT | 158.00 | 2733.3% | 18.8% |
| Net Profit | 126.00 | 940.0% | 38.5% |
| OPM | 7.33% | 4.89pp | 0.53pp |
| NPM | 4.26% | 4.81pp | 1.02pp |
| EPS | 0.24 | 900.0% | 33.3% |
Baxter Reports Q2 2026 Results, Sales Up 5% YoY
30 Jul 2026 · 30 Jul, 4:51 pm
Summary
Baxter International Inc. reported second-quarter 2026 results with worldwide sales of $2.96 billion, a 5% increase on both a reported and organic basis, driven by growth across all segments. The company reported U.S. GAAP diluted EPS of $0.26 and adjusted diluted EPS of $0.56. Management highlighted that second-quarter results exceeded expectations due to operating performance and a tariff refund, and the company has raised its full-year 2026 financial outlook.
Key Highlights
- 1
Second-quarter sales of $2.96 billion increased 5% on both a reported and organic basis, reflecting growth in all segments and divisions.
- 2
U.S. GAAP diluted earnings per share (EPS) for the second quarter was $0.26.
- 3
Adjusted diluted EPS for the second quarter was $0.56, a decrease of 5% from the prior year.
- 4
Medical Products & Therapies sales for the second quarter totaled approximately $2.1 billion, increasing 7% on a reported basis and 5% on an organic basis.
- 5
Healthcare Systems & Technologies sales for the second quarter totaled approximately $801 million, increasing 4% on both a reported and organic basis.
- 6
The company raised its full-year 2026 financial outlook for reported sales growth to 3% to 4% and adjusted earnings per diluted share to $1.95 to $2.15.
Management Comments
Andrew Hider
Our second-quarter results exceeded expectations on both the top and bottom lines, driven by both operating performance and an additional benefit from a tariff refund that was not previously contemplated in our guidance. While we’re encouraged by this steady progress and core operating momentum, we remain focused on the work ahead. Guided by the Baxter Growth and Performance System (GPS), we’re focused on further stabilizing the business, strengthening the balance sheet and driving a culture of continuous improvement as we build a stronger, more resilient company.
Informational and educational content only. Not investment advice.